Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera

Blood

Volumn 103, Issue 8, 2004, Pages 3200-3207

  Huang, Gang ^b   Shigesada, Katsuya ^b   Wee, Hee Jun ^b   Liu, P Paul ^b   Osato, Motomi ^b   Ito, Yoshiaki ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN; PROTEIN CBF BETA; PROTEIN PEBP2 BETA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CHROMOSOME 16; CHROMOSOME INVERSION; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; EMBRYO; GENETIC CODE; HETEROZYGOSITY; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE;

EID: 1842474806     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2188     Document Type: Article

References (43)

1. Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88:10431-10434.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064.
3. Ogawa E, Maruyama M, Kagoshima H, et al. PEBp2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A. 1993;90:6859-6863.
4. Ogawa E, Inuzuka M, Maruyama M, et al. Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α. Virology. 1993;194:314-331.
5. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983;309:630-636.
6. Liu PP, Hajra A, Wijmenga C, Collins FS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85:2289-2302.
7. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044.
8. Okuda T, van-Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
9. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444-3449.
10. Wang Q, Stacy T, Miller JD, et al. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell. 1996;87:697-708.
11. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 1997;94:5697-5702.
12. Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993;12:2715-2721.
13. Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res. 1994;54:1782-1786.
14. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15:303-306.
15. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the Runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemia. Blood. 1999;93:1817-1824.
16. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96:2862-2869.
17. Song W-J, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175.
18. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
19. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 1996;87:687-696.
20. Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23;144-146.
21. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukaemia. Cancer Cell. 2002;1:63-74.
22. Huang G, Shigesada K, Ito K, et al. Dimerization with PFBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20:723-733,
23. Lu J, Maruyama M, Satake M, et al. Subcellular localization of the α and β subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF. Mol Cell Biol. 1995;15:1651-1661.
24. Zhang Y-W, Bae S-C, Huang G, et al. A novel transcript encoding an N-terminally truncated AML1/PEBP2αB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol. 1997;17:4133-4145.
25. Kanno Y, Kanno T, Sakakura C, Bae S-C, Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor α (CBFα) subunit by the leukemia-related PEBP2/CBFβ-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol. 1998;18:4252-4261.
26. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18:2551-2562.
27. Kagoshima H, Akamatsu Y, Ito Y, Shigesada K. Functional dissection of the α and β subunits of transcription factor PEBP2 and the redox susceptibility of its DNA binding activity. J Biol Chem. 1996;271:33074-33082.
28. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts train chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
29. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD. The core binding factor (CBF) α interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem. 1998;273:31534-31540.
30. Adya N, Stacy T, Speck NA, Liu PP. The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates. Mol Cell Biol. 1998;18:7432-7443.
31. Sohn RL, Vikstrom KL, Strauss M, et al. A 29 residue region of the sarcomeric myosin rod is necessary for filament formation. J Mol Biol. 1997;266:317-330.
32. Kummalue T, Lou J, Friedman AD. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFβ-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol. 2002;22:8278-8291.
33. Ikebe M, Komatsu S, Woodhead JL, et al. The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin. J Biol Chem. 2001;276:30293-30300.
34. Liu PP, Wijmenga C, Hajira A, et al. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemic cells. Gene Chrom Cancer. 1996;16:77-87.
35. Cao W, Britos-Bray M, Claxton DF, et al. CBF β-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene. 1997;15:1315-1327.
36. Lutterbach B, Hou Y, Durst KL, Hiebert SW. The inv(16) encodes an acute myeloid leukemia 1 transcriptional compressor. Proc Natl Acad Sci U S A. 1999;96:12822-12827.
37. Miller JD, Stacy T, Liu PP, Speck NA. Core-binding factor β (CBFβ), but not CBFβ-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFβ-deficient embryonic stem cells. Blood. 2001;97:2248-2256.
38. Lukasik SM, Zhang L, Corpora T, et al. Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis. Nat Struct Biol. 2002;9:674-679.
39. Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW. The inv(16) fusion protein associates with compressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol. 2003;23:607-619.
40. Trybus KM, Lowey S. Conformational states of smooth muscle myosin: effects of light chain phosphorylation and ionic strength. J Biol Chem. 1984;259:8564-8571.
41. Trybus KM, Freyzon Y, Faust LZ, Sweeney HL. Spare the rod, spoil the regulation: necessity for a myosin rod. Proc Natl Acad Sci U S A. 1997;94:48-52.
42. Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol. 1998;16:1890-1896.
43. Grardel N, Roumier C, Soenen V, et al. Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFβ-MYH11 transcript: report of two new cases. Leukemia. 2002;16:150-151.